ImmunoGen (LSE:0A8K) - Aandelenkoers, Nieuws & Analyse

0A8K Overzicht aandelen

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. Meer informatie

0A8K fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	6/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 45.91% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar verwaterd

ImmunoGen, Inc. Concurrenten

Genus

LSE:GNS

UK£1.1b

Oxford Biomedica

LSE:OXB

UK£447.3m

Bioventix

AIM:BVXP

UK£195.7m

Avacta Group

AIM:AVCT

UK£182.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor ImmunoGen
Historische aandelenkoersen
Huidige aandelenkoers	US$31.24
52 Week Hoogtepunt	US$31.25
52 Week Laag	US$3.66
Bèta	1.17
11 maand verandering	4.80%
3 maanden verandering	97.21%
1 Jaar Verandering	658.25%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	307.73%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0A8K	GB Biotechs	GB Markt
7D	6.4%	1.5%	2.2%
1Y	658.3%	-17.9%	8.8%

Rendement versus industrie: 0A8K overtrof de UK Biotechs industrie, die het afgelopen jaar een rendement -17.9 % opleverde.

Rendement versus markt: 0A8K overtrof de UK markt, die het afgelopen jaar een rendement opleverde van 8.8 %.

Prijsvolatiliteit

Is 0A8K's price volatile compared to industry and market?
0A8K volatility
0A8K Average Weekly Movement	23.7%
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: De aandelenkoers van 0A8K is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 24% ) van 0A8K is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen UK.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1980	277	Mark Enyedy	www.immunogen.com

ImmunoGen, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van ImmunoGen zich tot de beurswaarde?
0A8K fundamentele statistieken
Marktkapitalisatie	US$8.36b
Inkomsten(TTM)	-US$73.52m
Inkomsten(TTM)	US$287.61m

29.1x

P/S-verhouding

-113.7x

Koers/Winstverhouding

Is 0A8K overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0A8K resultatenrekening (TTM)
Inkomsten	US$287.61m
Kosten van inkomsten	US$211.62m
Brutowinst	US$76.00m
Overige uitgaven	US$149.52m
Inkomsten	-US$73.52m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.27
Brutomarge	26.42%
Nettowinstmarge	-25.56%
Schuld/Eigen Vermogen Verhouding	12.8%

Hoe presteerde 0A8K op de lange termijn?

Bekijk historische prestaties en vergelijking

0A8K Overzicht aandelen

Beloningen

Risicoanalyse

ImmunoGen, Inc. Concurrenten

LSE:GNS

UK£1.1b

LSE:OXB

UK£447.3m

AIM:BVXP

UK£195.7m

AIM:AVCT

UK£182.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

New major risk - Share price stability

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold US$1.5m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.31 loss in 3Q 2022)

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

President recently sold US$17m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

Forecast breakeven date moved forward to 2024

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.24 loss in 2Q 2022)

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.095 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

ImmunoGen, Inc. Samenvatting